Companies

Aleor Dermaceuticals gets tentative USFDA nod for Efinaconazole topical solution

PTI New Delhi | Updated on April 08, 2021

Efinaconazole topical solution, 10 per cent, has an estimated market size of $233 mn for 12 months ending December 2020: IQVIA

Drug firm Alembic Pharmaceuticals on Thursday said its joint venture firm Aleor Dermaceuticals has received tentative approval from the US health regulator for Efinaconazole topical solution, used in the treatment of fungal toenail infections.

The tentatively approved product is therapeutically equivalent to the reference listed drug product Jublia topical solution, 10 per cent, of Bausch Health Americas.

Also read: Aleor’s ANDA for treatment of cutaneous candidiasis gets USFDA nod

Aleor Dermaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Efinaconazole topical solution, 10 per cent, Alembic Pharma said in a regulatory filing.

The solution is indicated for the topical treatment of onychomycosis of the toenails.

Quoting IQVIA data, Alembic Pharma said Efinaconazole topical solution, 10 per cent, has an estimated market size of $233 million for the 12 months ending December 2020.

Alembic has a total of 140 ANDA approvals (123 final approvals and 17 tentative approvals) from USFDA.

Published on April 08, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Alembic Pharmaceuticals Ltd
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.